Cardio3 appoints Atta Behfar
This article was originally published in Clinica
Executive Summary
Atta Behfar has joined Belgian biotech company Cardio3 as director for advanced research. Dr Behfar was one of the scientists involved in developing the firm's C-Cure stem cell-based therapy, and is a researcher at the Mayo Clinic in Rochester, Minnesota. In his new role, he will spend a year on assignment from the clinic to "develop and strengthen" Cardio3's research pipeline. He won the young investigator award at this year's American College of Cardiology meeting, held in March in Atlanta, Georgia, for his work on C-Cure. Mont-Saint-Guibert-based Cardio3 recently presented promising early data from the first human trial of the product, which is designed to heal damaged heart tissue by reprogramming the patient's own stem cells so that they become heart cells (www.clinica.co.uk, 30 June 2010).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.